Tyrosine kinase inhibitors such as gefitinib, erlotinib, neratinib, afatinib, dacomitinib, and osimertinib and monoclonal antibodies such as cetuximab, panitumumab, nimotuzumab, and necitumumab are used for treatments in cancers with EGFR dysregulation [11,12,13]. The gene discussed is EGFR; the disease is cancer.